Tags

Type your tag names separated by a space and hit enter

Outcome of peptic ulcer bleeding among users of traditional non-steroidal anti-inflammatory drugs and selective cyclo-oxygenase-2 inhibitors.
Aliment Pharmacol Ther. 2006 Nov 15; 24(10):1431-8.AP

Abstract

BACKGROUND

Few data exist on the impact of non-steroidal anti-inflammatory drug use on peptic ulcer outcome.

AIM

To examine the 30-day mortality from peptic ulcer bleeding associated with the use of traditional non-steroidal anti-inflammatory drugs and newer selective cyclo-oxygenase-2 inhibitors.

METHODS

Cohort study of patients with a first hospitalization for peptic ulcer bleeding in three Danish counties between 1991 and 2003. Data on pre-admission non-steroidal anti-inflammatory drug use, use of other ulcer-related drugs and comorbidities were obtained from population-based registries. Follow-up data on mortality were obtained from the Danish Civil Registry System.

RESULTS

Of 7,232 patients hospitalized for peptic ulcer bleeding, 28% were current non-steroidal anti-inflammatory drug users. Thirty-day mortality was 11% overall, and 13% among current non-steroidal anti-inflammatory drug users. Compared with never-use, the adjusted 30-day mortality rate ratios were 1.4 (95% CI: 1.1-1.9) for current use of non-steroidal anti-inflammatory drugs alone and 1.3 (95% CI: 1.0-1.7) for current use combined with other ulcer-related drugs. For users of celecoxib, alone and in combination, adjusted mortality rate ratios were 1.4 (95% CI: 0.5-3.9) and 2.0 (95% CI: 1.2-3.5), and for users of rofecoxib, 1.2 (95% CI: 0.4-3.9) and 0.9 (95% CI: 0.5-1.6).

CONCLUSION

Among patients hospitalized with peptic ulcer bleeding, use of non-steroidal anti-inflammatory drugs, including some newer cyclo-oxygenase-2 inhibitors, is associated with increased short-term mortality.

Authors+Show Affiliations

Department of Clinical Epidemiology, Aarhus University Hospital, Aalborg, Denmark. uxreth@aas.nja.dkNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17032286

Citation

Thomsen, R W., et al. "Outcome of Peptic Ulcer Bleeding Among Users of Traditional Non-steroidal Anti-inflammatory Drugs and Selective Cyclo-oxygenase-2 Inhibitors." Alimentary Pharmacology & Therapeutics, vol. 24, no. 10, 2006, pp. 1431-8.
Thomsen RW, Riis A, Christensen S, et al. Outcome of peptic ulcer bleeding among users of traditional non-steroidal anti-inflammatory drugs and selective cyclo-oxygenase-2 inhibitors. Aliment Pharmacol Ther. 2006;24(10):1431-8.
Thomsen, R. W., Riis, A., Christensen, S., McLaughlin, J. K., & Sørensen, H. T. (2006). Outcome of peptic ulcer bleeding among users of traditional non-steroidal anti-inflammatory drugs and selective cyclo-oxygenase-2 inhibitors. Alimentary Pharmacology & Therapeutics, 24(10), 1431-8.
Thomsen RW, et al. Outcome of Peptic Ulcer Bleeding Among Users of Traditional Non-steroidal Anti-inflammatory Drugs and Selective Cyclo-oxygenase-2 Inhibitors. Aliment Pharmacol Ther. 2006 Nov 15;24(10):1431-8. PubMed PMID: 17032286.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Outcome of peptic ulcer bleeding among users of traditional non-steroidal anti-inflammatory drugs and selective cyclo-oxygenase-2 inhibitors. AU - Thomsen,R W, AU - Riis,A, AU - Christensen,S, AU - McLaughlin,J K, AU - Sørensen,H T, Y1 - 2006/10/10/ PY - 2006/10/13/pubmed PY - 2007/5/22/medline PY - 2006/10/13/entrez SP - 1431 EP - 8 JF - Alimentary pharmacology & therapeutics JO - Aliment Pharmacol Ther VL - 24 IS - 10 N2 - BACKGROUND: Few data exist on the impact of non-steroidal anti-inflammatory drug use on peptic ulcer outcome. AIM: To examine the 30-day mortality from peptic ulcer bleeding associated with the use of traditional non-steroidal anti-inflammatory drugs and newer selective cyclo-oxygenase-2 inhibitors. METHODS: Cohort study of patients with a first hospitalization for peptic ulcer bleeding in three Danish counties between 1991 and 2003. Data on pre-admission non-steroidal anti-inflammatory drug use, use of other ulcer-related drugs and comorbidities were obtained from population-based registries. Follow-up data on mortality were obtained from the Danish Civil Registry System. RESULTS: Of 7,232 patients hospitalized for peptic ulcer bleeding, 28% were current non-steroidal anti-inflammatory drug users. Thirty-day mortality was 11% overall, and 13% among current non-steroidal anti-inflammatory drug users. Compared with never-use, the adjusted 30-day mortality rate ratios were 1.4 (95% CI: 1.1-1.9) for current use of non-steroidal anti-inflammatory drugs alone and 1.3 (95% CI: 1.0-1.7) for current use combined with other ulcer-related drugs. For users of celecoxib, alone and in combination, adjusted mortality rate ratios were 1.4 (95% CI: 0.5-3.9) and 2.0 (95% CI: 1.2-3.5), and for users of rofecoxib, 1.2 (95% CI: 0.4-3.9) and 0.9 (95% CI: 0.5-1.6). CONCLUSION: Among patients hospitalized with peptic ulcer bleeding, use of non-steroidal anti-inflammatory drugs, including some newer cyclo-oxygenase-2 inhibitors, is associated with increased short-term mortality. SN - 0269-2813 UR - https://www.unboundmedicine.com/medline/citation/17032286/Outcome_of_peptic_ulcer_bleeding_among_users_of_traditional_non_steroidal_anti_inflammatory_drugs_and_selective_cyclo_oxygenase_2_inhibitors_ L2 - https://doi.org/10.1111/j.1365-2036.2006.03139.x DB - PRIME DP - Unbound Medicine ER -